Skip to main content
SpringerLink
Log in

Myasthenia Gravis: Classification and Outcome Measurements

  • Chapter
  • First Online:
Myasthenia Gravis and Related Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

REFERENCES

  1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122–2128.

    Article  PubMed  CAS  Google Scholar 

  2. Barohn RJ. Standards of measurement in myasthenia gravis. Ann N Y Acad Sci 2003;998:432–439.

    Article  PubMed  Google Scholar 

  3. Jaretzki III A. Thymectomy for myasthenia gravis: analysis of the controversies regarding technique and result. Neurology 1997;48(suppl 5):S52–S63.

    Google Scholar 

  4. Jaretzki III A, Penn AS, Younger DS, Wolff M, Olarte MR, Lovelace RE, et al. “Maximal” thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg 1988;95:747–757.

    PubMed  Google Scholar 

  5. Jaretzki III A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55:16–23.

    PubMed  Google Scholar 

  6. Osserman KE. Clinical aspects. In: Osserman KE, editor. Myasthenia Gravis. New York: Grune & Stratton; 1958. pp. 79–80.

    Google Scholar 

  7. Osserman KE, Kornfeld P, Cohen E, Genkins G. Studies in myasthenia gravis: review of two hundred eighty-two cases at the Mount Sinai Hospital, New York City. Arch Int Med 1958;102:72–81.

    Article  CAS  Google Scholar 

  8. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;38:497–537.

    PubMed  CAS  Google Scholar 

  9. Barohn RJ, Jackson CE. New classification system for myasthenia gravis (abstract). J Child Neurol 1994;9:205.

    Google Scholar 

  10. Besinger UA, Toyka KV, Heininger K, et al. Long-term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis. Ann NY Acad Sci 1981;377:812–815.

    Article  Google Scholar 

  11. Olanow CW, Wechsler AS, Sirotkin-Roses M, Stajich J, Roses AD. Thymectomy as primary therapy in myasthenia gravis. Ann NY Acad Sci 1987;505:595–606.

    Article  PubMed  CAS  Google Scholar 

  12. Wolfe GI, Barohn RJ. Neuromuscular junction disorders of childhood. In: Swaiman KF, Ashwal S, Ferriero DM, editors. Pediatric Neurology: Principles and Practice. 4th ed. Philadelphia: Mosby Elsevier; 2006. pp. 1941–1968.

    Google Scholar 

  13. Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann N Y Acad Sci 1981;377:678–690.

    Article  PubMed  CAS  Google Scholar 

  14. Wolfe GI, Kaminski HJ, Jaretzki III A, Swan A, Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann NY Acad Sci 2003;998:473–480.

    Article  PubMed  CAS  Google Scholar 

  15. Kawaguchi N, Kuwabara S, Nemoto Y, Fukutake T, Satomura Y, Arimura K, et al. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999–2000. J Neurol Sci 2004;224:43–47.

    Article  PubMed  Google Scholar 

  16. Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316–1321.

    PubMed  CAS  Google Scholar 

  17. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539–551.

    Article  PubMed  CAS  Google Scholar 

  18. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719–724.

    Article  PubMed  CAS  Google Scholar 

  19. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the Quantitative Myasthenia Gravis Score. Ann NY Acad Sci 1998;841:769–772.

    Article  PubMed  CAS  Google Scholar 

  20. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle & Nerve 2002;26:549–552.

    Article  CAS  Google Scholar 

  21. Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000;246:286–289.

    Article  Google Scholar 

  22. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968–1970.

    Article  PubMed  CAS  Google Scholar 

  23. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and toleratibility. Neurology 2003;61:1438–40.

    PubMed  CAS  Google Scholar 

  24. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Eur Neurol 2005;53:146–150.

    Article  PubMed  CAS  Google Scholar 

  25. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187–190.

    Article  PubMed  Google Scholar 

  26. Rowin J, Meriggioli MN, Tüzün E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004;63:2390–2392.

    PubMed  CAS  Google Scholar 

  27. Barohn RJ. Video: how to administer the quantitative myasthenia test. Myasthenia Gravis Foundation of America, Inc. 1821 University Ave.W. Suite S256,St. Paul, MN 55104; 1996.

    Google Scholar 

  28. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis. Ann N Y Acad Sci 2003;998:440–444.

    Article  PubMed  Google Scholar 

  29. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97–99.

    PubMed  CAS  Google Scholar 

  30. Gajdos P, Simon N, de Rohan Chabot P, Goulon M. Effets a long terme des echanges plasmatiques au cours de la myasthenie. Resultats d'une etude randomisee. Presse Med 1983;12:939–942.

    PubMed  CAS  Google Scholar 

  31. Gajdos P, Sharshar T, Chevret S. Standards of measurement in myasthenia gravis. Ann N Y Acad Sci 2003;998:445–452.

    Article  PubMed  CAS  Google Scholar 

  32. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487–1489.

    PubMed  CAS  Google Scholar 

  33. Takamori M, Motomura M, Kawaguchi N, Nemoto Y, Hattori T, Yoshikawa Y, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004;62:1894–1896.

    PubMed  CAS  Google Scholar 

  34. Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opinions 2004;20:1269–1273.

    Article  CAS  Google Scholar 

  35. Herbelin LL, Nations SP, Wolfe GI, Foster BM, Bryan WW, Barohn RJ. The correlation between static fatigue testing and the quantitative myasthenia gravis score and activities of daily living profile (abstract). Neurology 2001;56:A63.

    Google Scholar 

  36. Ponseti JM, Azem J, Fort JM, López-Cano M, R V, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005;64:1641–1643.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Texas Southwestern Medical School, Dallas, TX

    Gil I. Wolfe MD

  2. Department of Neurology, University of Kansas Medical Center, Kansas City, KS

    Richard J. Barohn MD

Authors
  1. Gil I. Wolfe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Barohn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Wolfe, G.I., Barohn, R.J. (2009). Myasthenia Gravis: Classification and Outcome Measurements. In: Myasthenia Gravis and Related Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1007/978-1-59745-156-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-156-7_18

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-852-2

  • Online ISBN: 978-1-59745-156-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation